Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis

被引：30

作者：

De Stefano, Nicola ^{[1
]}

Curtin, Francois ^{[2
,7
]}

Stubinski, Bettina ^{[2
,7
]}

Blevins, Gregg ^{[3
]}

Drulovic, Jelena ^{[4
]}

Issard, Delphine ^{[2
,7
]}

Shotekov, Penko ^{[5
]}

Gasperini, Claudio ^{[6
]}

机构：

[1] Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy

[2] Merck Serono SA, Geneva, Switzerland

[3] Univ Alberta, Div Neurol, Edmonton, AB, Canada

[4] Univ Belgrade, Inst Neurol, Clin Ctr Serbia, Belgrade, Serbia

[5] UMBAL Alexandovska, Neurol Clin, Sofia, Bulgaria

[6] San Camillo Forlanini Hosp, Rome, Italy

[7] Merck KGaA, Darmstadt, Germany

来源：

MULTIPLE SCLEROSIS JOURNAL | 2010年 / 16卷 / 07期

关键词：

efficacy; interferon beta-1a; magnetic resonance imaging; randomized controlled trial; relapsing-remitting multiple sclerosis;

D O I：

10.1177/1352458510362442

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

w This study evaluated the efficacy of a new formulation of subcutaneous (sc) interferon (IFN)-beta 1a in relapsing-remitting multiple sclerosis (RRMS). Patients (n=180) were randomized (2:1) to IFN-beta 1a or placebo for 16 weeks; all patients then received IFN-beta 1a for 24 weeks. Monthly brain MRI was performed. At week 16, the mean number of combined unique active (CUA) lesions was lower with IFN-beta 1a than with placebo (p < 0.001; 69% fewer lesions). The mean cumulative number of CUA lesions was already lower with IFN-beta 1a by week 4 ( post hoc analysis; p=0.015). The new formulation of sc IFN-beta 1a has rapid beneficial effects on MRI outcomes in RRMS.

引用

页码：888 / 892

页数：5

共 8 条

[1] Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results [J].